NAVIDEA BIOPHARM. DL-001 Watch

from S-1/A 38 pages Navidea Biopharmaceuticals, Inc. Dealer-Manager Agreement

from 8-K 51 pages Navidea Biopharmaceuticals, Inc. 8,000,000 Common Stock (Par Value $.001 Per Share) Underwriting Agreement

from 8-K 20 pages 2,100,000 Shares Navidea Biopharmaceuticals, Inc. Common Stock Underwriting Agreement

from 8-K 22 pages 1,542,389 Shares Navidea Biopharmaceuticals, Inc. Common Stock Underwriting Agreement

from SC 13G 1 page Joint Filing Agreement

from SC 13G/A 1 page Joint Filing Agreement

from 8-K 15 pages Confidential David C. Bupp CEO Neoprobe Corp. 425 Metro Place North Suite 300 Dublin, Oh 43017 Dear Mr. Bupp

from NT 10-K 1 page <page> 1 Exhibit 1 Neoprobe Corporation 425 Metro Place North Suite 300 Dublin, Ohio 43017 March 31, 1999 Attention: Brent Larson, Chief Financial Officer as of This Date, We Are Unable to Issue Our Opinion on Neoprobe Corporation's Consolidated Financial Statements as of December 31, 1998, and for the Year Then Ended, as We Have Not Completed Our Audit. We Appreciate the Company's Cooperation to Date and Expect It to Continue as We Complete Our Audit. We Fully Expect to Render Our Opinion in the Next Fifteen Business Days. Very Truly Yours, Kpmg Llp /S/ Jonathon S. Eesley Partner